Carvix
Definitive (DA signed)Profile in progress
- What it is
- A private company preparing to list via a SPAC merger. Full profile in progress.
- What it’s doing now
- Merging with Crown Reserve Acquisition Corp. I (CRAC) — definitive (da signed), announced Mar 30, 2026.
- What you should know
- The real share count puts the effective valuation 59% above the announced $500M. The deal carries a $10M minimum-cash condition — heavy redemptions can break it.
What the company says about itself
Web research — not audited[WEB-INTEL 2026-08-25] 5 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The transaction values Carvix at an implied enterprise value of $1.0 billion, including earnout consideration, with existing Carvix stockholders receiving Crown Reserve common stock in an all-stock transaction based on a $10.00 per share re" [https://www.stocktitan.net/news/CRACR/crown-reserve-acquisition-corp-i-and-carvix-inc-announce-definitive-j1s0vmmppkdo.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Crown Reserve has agreed to use reasonable best efforts to raise a minimum of $80.0 million in PIPE financing and a committed equity line of credit of no less than $20.0 million." [https://www.stocktitan.net/news/CRACR/crown-reserve-acquisition-corp-i-and-carvix-inc-announce-definitive-j1s0vmmppkdo.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The transaction requires a minimum of $10.0 million in cash at closing after redemptions, deferred underwriting fees, repayment of indebtedness and transaction expenses." [https://www.stocktitan.net/news/CRACR/crown-reserve-acquisition-corp-i-and-carvix-inc-announce-definitive-j1s0vmmppkdo.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Certain Carvix stockholders will be eligible to receive up to 50,000,100 additional shares of Crown Reserve common stock over a four-year earnout period beginning January 1, 2027, tied to annual revenue and EBITDA targets." [https://www.stocktitan.net/news/CRACR/crown-reserve-acquisition-corp-i-and-carvix-inc-announce-definitive-j1s0vmmppkdo.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Closing is subject to customary approvals and a Sept 30, 2026 outside date." [https://www.stocktitan.net/news/CRACR/crown-reserve-acquisition-corp-i-and-carvix-inc-announce-definitive-j1s0vmmppkdo.html] [WEB-INTEL 2026-08-25] 5 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The transaction values Carvix at an implied enterprise value of $1.0 billion, including earnout consideration, with existing Carvix stockholders receiving Crown Reserve common stock in an all-stock transaction based on a $10.00 per share re" [https://www.stocktitan.net/news/CRACR/crown-reserve-acquisition-corp-i-and-carvix-inc-announce-definitive-j1s0vmmppkdo.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Crown Reserve has agreed to use reasonable best efforts to raise a minimum of $80.0 million in PIPE financing and a committed equity line of credit of no less than $20.0 million." [https://www.stocktitan.net/news/CRACR/crown-reserve-acquisition-corp-i-and-carvix-inc-announce-definitive-j1s0vmmppkdo.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The transaction requires a minimum of $10.0 million in cash at closing after redemptions, deferred underwriting fees, repayment of indebtedness and transaction expenses." [https://www.stocktitan.net/news/CRACR/crown-reserve-acquisition-corp-i-and-carvix-inc-announce-definitive-j1s0vmmppkdo.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Certain Carvix stockholders will be eligible to receive up to 50,000,100 additional shares of Crown Reserve common stock over a four-year earnout period beginning January 1, 2027, tied to annual revenue and EBITDA targets." [https://www.stocktitan.net/news/CRACR/crown-reserve-acquisition-corp-i-and-carvix-inc-announce-definitive-j1s0vmmppkdo.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Closing is subject to customary approvals and a Sept 30, 2026 outside date." [https://www.stocktitan.net/news/CRACR/crown-reserve-acquisition-corp-i-and-carvix-inc-announce-definitive-j1s0vmmppkdo.html] [WEB-INTEL 2026-08-25] 5 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The transaction values Carvix at an implied enterprise value of $1.0 billion, including earnout consideration" [https://www.stocktitan.net/news/CRACR/crown-reserve-acquisition-corp-i-and-carvix-inc-announce-definitive-j1s0vmmppkdo.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Crown Reserve has agreed to use reasonable best efforts to raise a minimum of $80.0 million in PIPE financing and a committed equity line of credit of no less than $20.0 million" [https://www.stocktitan.net/news/CRACR/crown-reserve-acquisition-corp-i-and-carvix-inc-announce-definitive-j1s0vmmppkdo.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The transaction requires a minimum of $10.0 million in cash at closing after redemptions, deferred underwriting fees, repayment of indebtedness and transaction expenses" [https://www.stocktitan.net/news/CRACR/crown-reserve-acquisition-corp-i-and-carvix-inc-announce-definitive-j1s0vmmppkdo.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Certain Carvix stockholders will be eligible to receive up to 50,000,100 additional shares of Crown Reserve common stock over a four-year earnout period beginning January 1, 2027" [https://www.stocktitan.net/news/CRACR/crown-reserve-acquisition-corp-i-and-carvix-inc-announce-definitive-j1s0vmmppkdo.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Closing is subject to customary approvals and a Sept 30, 2026 outside date" [https://www.stocktitan.net/news/CRACR/crown-reserve-acquisition-corp-i-and-carvix-inc-announce-definitive-j1s0vmmppkdo.html] [WEB-INTEL 2026-08-25] 3 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The transaction requires a minimum of $10.0 million in cash at closing after redemptions, deferred underwriting fees, repayment of indebtedness and transaction expenses." [https://www.stocktitan.net/news/CRACR/crown-reserve-acquisition-corp-i-and-carvix-inc-announce-definitive-j1s0vmmppkdo.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "closing is subject to customary approvals and a Sept 30, 2026 outside date." [https://www.stocktitan.net/news/CRACR/crown-reserve-acquisition-corp-i-and-carvix-inc-announce-definitive-j1s0vmmppkdo.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Deal termination date set for Sept 30, 2026" [https://www.stocktitan.net/news/CRACR/crown-reserve-acquisition-corp-i-and-carvix-inc-announce-definitive-j1s0vmmppkdo.html] [WEB-INTEL 2026-08-25] 5 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The transaction values Carvix at an implied enterprise value of $1.0 billion, including earnout consideration, with existing Carvix stockholders receiving Crown Reserve common stock in an all-stock transaction based on a $10.00 per share re" [https://www.stocktitan.net/news/CRACR/crown-reserve-acquisition-corp-i-and-carvix-inc-announce-definitive-j1s0vmmppkdo.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Crown Reserve has agreed to use reasonable best efforts to raise a minimum of $80.0 million in PIPE financing and a committed equity line of credit of no less than $20.0 million." [ht [WEB-INTEL 2026-08-26] 5 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The transaction values Carvix at an implied enterprise value of $1.0 billion, including earnout consideration" [https://www.stocktitan.net/news/CRACR/crown-reserve-acquisition-corp-i-and-carvix-inc-announce-definitive-j1s0vmmppkdo.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Crown Reserve has agreed to use reasonable best efforts to raise a minimum of $80.0 million in PIPE financing and a committed equity line of credit of no less than $20.0 million" [https://www.stocktitan.net/news/CRACR/crown-reserve-acquisition-corp-i-and-carvix-inc-announce-definitive-j1s0vmmppkdo.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The transaction requires a minimum of $10.0 million in cash at closing after redemptions, deferred underwriting fees, repayment of indebtedness and transaction expenses" [https://www.stocktitan.net/news/CRACR/crown-reserve-acquisition-corp-i-and-carvix-inc-announce-definitive-j1s0vmmppkdo.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Certain Carvix stockholders will be eligible to receive up to 50,000,100 additional shares of Crown Reserve common stock over a four-year earnout period beginning January 1, 2027" [https://www.stocktitan.net/news/CRACR/crown-reserve-acquisition-corp-i-and-carvix-inc-announce-definitive-j1s0vmmppkdo.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Closing is subject to customary approvals and a Sept 30, 2026 outside date" [https://www.stocktitan.net/news/CRACR/crown-reserve-acquisition-corp-i-and-carvix-inc-announce-definitive-j1s0vmmppkdo.html]
Source: company web presence · marketing claims are reported as claims, never merged into the filed figures above.
The deal it’s entering
Carvix is merging with Crown Reserve Acquisition Corp. I (CRAC), a $173M SPAC currently marked Deal announced and trading at $10.20 against $10.23 in trust per share.
| Headline equity value | $500M |
| Effective valuation (all shares) | $796M+59% vs headline |
| Sponsor promote | 20% |
| PIPE | $80MMinimum PIPE Investment Amount defined as a closing condition (not a signed subscription) |
| Minimum cash to close | $10M |
Structure per SEC accession(s) 0001213900-26-040029, 0001213900-26-038670, 0001213900-26-040025. How to read these numbers: headline vs effective valuation · what a definitive agreement commits
What exactly is being valued, and at what
What the filings actually value
The combined company net of that cash — what the buyers are paying for the BUSINESS. Every multiple below is struck on this figure and on nothing else.
What that price is, per dollar of sales
Enterprise value ÷ EBITDA — not shown
No EBITDA figure for Carvix, Inc. appears in any filing we hold, so no EV/EBITDA multiple is shown. We have not inferred one from a margin assumption — a multiple built on an assumed margin measures the assumption, not the company.
All figures above are stated in EX-99 press release0001213900-26-038670
EX-99 press release, 0001213900-26-038670: proFormaEnterpriseValueM "$1.0 billion". A press release is a party's own claim, not a filed table: any stated capitalisation table supersedes it.
Was this deal done at an expensive or a cheap valuation?
SpacBrain’s read on the price
No multiple can be computed
We hold no revenue figure in US dollars for Carvix, Inc., so there is nothing to divide the price by and no multiple can be struck. It is not recorded as pre-revenue either — this is a gap in our record, not a finding that the company has no sales. The deal values it at $1bn regardless.
We have not extracted a revenue figure for this company from its filings yet. That is our gap, not a statement about the business.
Pro-forma enterprise value as filed.
Not extracted from the filings yet.
Not computable — no revenue figure has been extracted from the filings yet.
No listed comparable carries a revenue multiple we can use.
Common questions
Is Carvix going public?
Carvix has a signed merger with the SPAC Crown Reserve Acquisition Corp. I (CRAC), announced Mar 30, 2026. Deal status: Definitive (DA signed).
What is Carvix's SPAC deal valuation?
The announced headline equity value is $500M, but counting every share class — founder promote, PIPE and public shares — the effective valuation is $796M, 59% above the headline.
Was Carvix bought at an expensive or a cheap valuation?
We hold no revenue figure in US dollars for Carvix, Inc., so there is nothing to divide the price by and no multiple can be struck. It is not recorded as pre-revenue either — this is a gap in our record, not a finding that the company has no sales. The deal values it at $1bn regardless.
Does Carvix have revenue?
The filings we've parsed don't state a usable revenue figure yet; this profile is updated as new documents land.
Educational content, not investment advice.